Short answer
CASTLE BIOSCIENCES INC (CSTL) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 released July 30, 2026.
CASTLE BIOSCIENCES INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 released July 30, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1
- Results provided under Regulation FD through a press release, not Section 18 “filed” information
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.2 provides investor presentation materials for management’s future meetings
- Presentation may contain updated company strategy, operating information, or business outlook relevant to valuation
- Regulation FD disclosure expands public access to information shared in investor communications
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $103.5M, up from $86.2M, with core test reports up 32%
- TissueCypher reports surged to 14,988 from 9,170, offsetting modest DecisionDx-Melanoma growth
- 2026 revenue guidance raised to $365–375M from $345–355M, signaling stronger demand expectations
- Profitability outlook improved with positive Adjusted EBITDA expected in Q3, Q4 and full-year 2026
- Q2 GAAP net loss $2.1M versus $4.5M income, while Adjusted EBITDA rose to $12.4M from $10.4M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CASTLE BIOSCIENCES INC 8-K filings
Get the next CSTL 8-K as it lands
Follow CSTL for push alerts, or ask the research agent what this filing means.